Physician profile
Victor Abdow
NPI 1306806872
$58,312.14
in general payments reported to CMS, 2019-2025
24 companies · $8,706 in 2025
The $8,706 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,409 · 2020: $525 · 2021: $3,584 · 2022: $7,300 · 2023: $15K · 2024: $16K · 2025: $8,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $31K · Food and Beverage: $4,350 · Consulting Fee: $3,080 · Travel and Lodging: $1,239 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $30,800.00 |
| Food and Beverage | $4,349.98 |
| Consulting Fee | $3,080.00 |
| Travel and Lodging | $1,238.62 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $50,552.71 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $3,992.38 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $611.64 | 2021-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $590.45 | 2021-2024 | Sogroya, Norditropin, Saxenda |
| Kaleo, INC. | $396.84 | 2019-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $366.59 | 2019-2025 | Enflonsia, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $294.05 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $259.92 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $151.05 | 2019-2025 | Pediarix, Bexsero, Penmenvy |
| Rhythm Pharmaceuticals, INC. | $142.66 | 2023-2024 | Imcivree, Imcivree |
| Cranial Technologies, INC | $131.81 | 2019-2024 | Doc Band |
| Tolmar, INC. | $106.30 | 2023-2024 | |
| Sanofi Pasteur INC. | $85.15 | 2020-2023 | |
| Alk-Abello, INC | $81.30 | 2025 | Neffy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $62.26 | 2022-2025 | Flumist Quadrivalent |
| Vertical Pharmaceuticals, LLC | $54.40 | 2024-2025 | Relexxii |
| Tolmar Pharmaceuticals, INC. | $48.03 | 2022 | |
| Arbor Pharmaceuticals, INC. | $41.15 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $28.01 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $22.89 | 2024 | |
| Neos Therapeutics, LP | $18.37 | 2024 | Adzenys Xr-Odt |
| Genentech USA, INC. | $16.03 | 2021 | |
| Pfizer INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Abdow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.